?>
Contact us
Follow Us
About Us
Members
Executive Director
Why Biosimilars
The Issue
Our Solutions
Biosimilars 101
Foundations
Core Principles
FDA Regulatory Tenets
Biosimilars FAQs
Future Evolution of Biosimilar Development
Approved Biosimilars
Advocacy
Our Action
Tools
News
Resources
Get Involved
Partners
Archives:
Resources
Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
March 15, 2024
signalgroup
Letter of Support for PBM Reform
November 3, 2023
signalgroup
Setting the Record Straight on Biosimilar Interchangeability
November 1, 2023
signalgroup
Transitioning from a Reference Biologic to a Biosimilar is Safe and Effective
August 24, 2023
signalgroup
Biosimilars: Non-Medical Switching and Transitioning
August 7, 2023
signalgroup
Streamlining Biosimilar Development: The Developer’s Perspective One-Pager
April 5, 2023
signalgroup
Biosimilars Forum Comments on BsUFA III Research Roadmap
December 20, 2022
signalgroup
Shared Savings Programs in Europe
October 4, 2022
signalgroup
Inflation Reduction Act – ASP+8 Biosimilars Payment Increase
September 26, 2022
signalgroup
Biosimilars: Non-Medical Switching and Transitioning
August 3, 2022
signalgroup
Humira® Biosimilars: Reaching the Market’s Cost-Savings Potential
01
02
03
04